Efficacy and Safety of Replacing Lenalidomide with Pomalidomide for Patients with Multiple Myeloma Refractory to a Lenalidomide-Containing Combination Regimen

The combination of pomalidomide with dexamethasone is approved for the treatment of relapsed/refractory multiple myeloma (RRMM). This phase 2, multicenter, open-label, non-randomized study investigated pomalidomide as a replacement for lenalidomide for 45 patients with RRMM refractory to a lenalidomide-containing combination regimen containing steroids and one or more other anti-myeloma agents administered using the same schedule(s), dose(s), and drug combination. Pomalidomide was administered on days 1–21 of a 28-day cycle for ≤8 cycles at a dose of 2, 3, or 4 mg.